Skip to main content

Table 4 Response among patients with AML-MRC preselected to receive LDAC and treated with azacitidine or LDAC

From: Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

Patients with AML-MRC preselected to receive LDAC (n = 160)
  AZA (n = 81) LDAC (n = 79)
n (%)
Overall Response Rate (CR + CRi) 22 (27.2) 11 (13.9)
CR 17 (21.0) 10 (12.7)
CRi 5 (6.2) 1 (1.3)
Partial remission 1 (1.2) 1 (1.3)
Stable disease 30 (37.0) 30 (38.0)
Progressive disease 4 (4.9) 11 (13.9)
  LDAC-preselected Intermediate-risk cytogenetics LDAC-preselected Poor-risk cytogenetics
AZA (n = 47) LDAC (n = 33) AZA (n = 34) LDAC (n = 46)
n (%)
Overall Response Rate (CR + CRi) 15 (31.9) 6 (18.2) 7 (20.6) 5 (10.9)
CR 12 (25.5) 6 (18.2) 5 (14.7) 4 (8.7)
CRi 3 (6.4) 0 2 (5.9) 1 (2.2)
Partial remission 1 (2.1) 1 (3) 0 0
Stable disease 19 (40.4) 15 (45.5) 11 (32.4) 15 (32.6)
Progressive disease 4 (8.5) 2 (6.1) 0 9 (19.6)
  LDAC-preselected age 65–74 years LDAC-preselected age ≥ 75 years
AZA (n = 26) LDAC (n = 38) AZA (n = 55) LDAC (n = 41)
n (%)
Overall Response Rate (CR + CRi) 10 (38.5) 7 (18.4) 12 (21.8) 4 (9.8)
CR 7 (26.9) 6 (15.8) 10 (18.2) 4 (9.8)
CRi 3 (11.5) 1 (2.6) 2 (3.6) 0
Partial remission 0 1 (2.6) 1 (1.8) 0
Stable disease 9 (34.6) 18 (47.4) 21 (38.2) 12 (29.3)
Progressive disease 2 (7.7) 4 (10.5) 2 (3.6) 7 (17.1)
  1. AML-MRC, AML with myelodysplasia-related changes; AZA, azacitidine; CR, complete remission; CRi, CR with incomplete blood count recovery; LDAC, low-dose cytarabine